Cassava Sciences: With Almost Half The Float Shorted, Results Could Be Interesting

Summary:

• Cassava Sciences’ stock is highly shorted, with potential reward tied to the upcoming Phase 3 trial results for simufilam.
• The bull thesis hinges on simufilam outperforming current treatments or showing efficacy in specific subgroups.
• Mixed trial results could still offer a path forward, but the stock’s unpredictable nature and meme-stock characteristics add to the investment risk.
• SAVA had $149 million cash in hand at the end of the third quarter of 2024.

Thesis

In light of Cassava Sciences’ (NASDAQ:SAVA) most recent earnings report, it is time to take a look at what lies ahead for the company.

The company is among the most shorted stocks on Wall Street, with a short

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.